Valley National Advisers’s Alaunos Therapeutics TCRT Stock Holding History

Valley National Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-67	Closed	-$43K	–	818
2019 Q3	$43K	Buy	+67	New	+$53.1K	0.01%	323
2017 Q4	–	Sell	-1	Closed	-$1K	–	716
2017 Q3	$1K	Hold	1	–	–	﹤0.01%	626
2017 Q2	$1K	Sell	1 -2	-67%	-$1.96K	﹤0.01%	575
2017 Q1	$3K	Hold	3	–	–	﹤0.01%	514
2016 Q4	$2K	Hold	3	–	–	﹤0.01%	570
2016 Q3	$2K	Hold	3	–	–	﹤0.01%	543
2016 Q2	$2K	Hold	3	–	–	﹤0.01%	539
2016 Q1	$3K	Hold	3	–	–	﹤0.01%	507
2015 Q4	$3K	Hold	3	–	–	﹤0.01%	509
2015 Q3	$4K	Hold	3	–	–	﹤0.01%	469
2015 Q2	$5K	Buy	+3	New	+$4.66K	﹤0.01%	452

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Valley National Advisers's TCRT Position: Q4 2019 in Review

Valley National Advisers sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 67 shares — an estimated $43K sold.

Valley National Advisers first reported a position in TCRT in Q2 2015 and held it in 11 quarters. The position peaked at $43K in Q3 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

Valley National Advisers reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
Valley National Advisers sold 67 Alaunos Therapeutics shares in Q4 2019, an estimated $43K.
Valley National Advisers first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 11 quarters.
Valley National Advisers's Alaunos Therapeutics position peaked at $43K in Q3 2019.
148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on Valley National Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.